Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Clearside Biomedical (CLSD) Weakness a Buying Opportunity - Wedbush
December 9, 2016 12:29 PM ESTWedbush analyst Liana Moussatos reiterated an Outperform rating and $28 price target on Clearside Biomedical (NASDAQ: CLSD), saying weakness is unwarranted and represents a buying opportunity.
"Investor sentiment declined for drug stocks following recent unexpected political comments about decreasing drug pricing," Moussatos... More
